Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

Recruiting

Phase 1

Avutometinib, Defactinib, EverolimusPhase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT07318324

Conditions

Phase IB

Avutometinib

RAS Pathway

Endometrial

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Avutometinib

defactinib

Everolimus

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-28. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-06-29.